TARRIFF SCOTT (CEO) sold 3.8% of their position (21.62K shares) of EAGLE PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $299.3K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 11/3/2023ACC: 0001209191-23-054333
DirectorOfficer· CEO
Since Jun 2018
-21.62K
Net shares
Net seller
$299.3K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
21.62K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−10.93K
Price / share
$13.82
Trade value
$150.98K
% of position
1.9%
11/1/2023
567.07K→556.14K
Common Stock
Direct
Shares
−10.69K
Price / share
$13.87
Trade value
$148.33K
% of position
1.9%
11/2/2023
556.14K→545.45K
Total
Net shares
−21.62K
Net value
-$299.31K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/1/2023 | S · Sale | −10.93K | $13.82 | $150.98K | 1.9% | 567.07K | 556.14K |
| Common Stock Direct | 11/2/2023 | S · Sale | −10.69K | $13.87 | $148.33K | 1.9% | 556.14K | 545.45K |
| Total | −21.62K | -$299.31K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned992.62K
Total
992.62K indirect992.62K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 992.62K | Indirect |
| Total | 992.62K | 992.62K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported